BibTex RIS Cite

In-vitro activity of oxymino-cephalosporins with and without sulbactam against Class A Extended-spectrum β-lactamase producing E.coli

Year 2011, Volume: 1 Issue: 03, 87 - 92, 01.09.2011
https://doi.org/10.5799/ahinjs.02.2011.03.0022

Abstract

Objectives: The primary aim of this study was to determine the activities of ceftazidime and cefepime combined to sulbactam against class A extended-spectrum β lactamases (ESBLs). Materials and methods: Eight university hospitals participated to the study by submitting isolates those were recovered during a six-month period in 2010 from various clinical materials. Sulbactam was tested in two fixed concentrations of 4 mg/l and 8 mg/l. Isolates showing a fourfold or more decrease in the MIC of an oxyimino-cephalosporin with sulbactam were defined as ESBL producers. Isolates were screened for CTX-M group 1 extended-spectrum β lactamases by PCR. Results: A total of 149 ESBL-positive E.coli were studied. Isolates were uniformly susceptible to carbapenems and highly resistant to ciprofloxacin. According to CLSI breakpoints, 28% (42/149) of isolates were susceptible to ceftazidime and 32% (47/149) to cefepime. With 4 mg/L and 8 mg/L sulbactam supplement, ceftazidime susceptibility rose to 69% (103/149) and 88% (131/149), while cefepime susceptibility rose to 86 % (128/149) and 95% (141/149), respectively. PCR screening revealed that 63% (94/149) of the isolates were positive for blaCTX-M and 38% (36/94) of these were on the O25b-ST131 clone. Conclusion: Ceftazidime plus sulbactam and cefepime plus sulbactam showed remarkable activity against ESBL-positive E.coli.

References

  • Bush K, Jacoby GA. Updated functional classification of beta- lactamases. Antimicrob Agents Chemother 2010; 54:969- 976.
  • Akinci E, Vahaboglu H. Minor extended-spectrum β-lactamases. Expert Rev Anti Infect Ther 2010; 8:1251-1258.
  • Coque TM, Novais A, Carattoli A et al. Dissemination of clon- ally related Escherichia coli strains expressing extended- spectrum beta-lactamase CTX-M-15. Emerg Infect Dis 2008; 14:195-200.
  • Nicolas-Chanoine M, Blanco J, Leflon-Guibout V et al. Inter- continental emergence of Escherichia coli clone O25:H4- ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 61:273-281.
  • Marchaim D, Gottesman T, Schwartz O et al. National multi- center study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae produc- ing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2010; 54:5099-5104.
  • Tumbarello M, Sanguinetti M, Montuori E et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacte- riaceae: importance of inadequate initial antimicrobial treat- ment. Antimicrob Agents Chemother 2007; 51:1987-1994.
  • Clinical and Laboratory Standards Institute (2010.): Perfor- mance standards for antimicrobial susceptibility testing. Twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI; 2010 CLSI.
  • Clermont O, Dhanji H, Upton M et al. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother 2009; 64:274-277.
  • Vahaboglu H, Budak F, Kasap M et al. High prevalence of OXA-51-type class D beta-lactamases among ceftazidime- resistant clinical isolates of Acinetobacter spp.: co-existence with OXA-58 in multiple centres. J Antimicrob Chemother 2006; 58:537-542.
  • European Committee on Antimicrobial Susceptibility Testing (EUCAST). European Committee on Antimicrobial Suscepti- bility Testing (EUCAST) http://www.eucast.org [accessed 26 May 2010].
  • Akhan S, Coskunkan F, Tansel O, Vahaboglu H. Conjugative resistance to tazobactam plus piperacillin among extended- spectrum beta-lactamase-producing nosocomial Klebsiella pneumoniae. Scand J Infect Dis 2001; 33:512-515.
  • Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hsueh P. Comparison of CLSI 2009, CLSI 2010 and EUCAST ceph- alosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxy- toca from the SMART Global Surveillance Study. Int J Anti- microb Agents 2010; 36:293-294.
  • Foulds G, Stankewich JP, Marshall DC et al. Pharmacokinet- ics of sulbactam in humans. Antimicrob Agents Chemother 1983; 23:692-699.
  • Pfaller MA, Barry AL, Fuchs PC, Gerlach EH, Hardy DJ, McLaughlin JC. Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-nega- tive bacilli to ampicillin and ampicillin/sulbactam. Eur J Clin Microbiol Infect Dis 1993; 12:356-362.
  • Gur D, Hascelik G, Aydin N et al. Antimicrobial resistance in gram-negative hospital isolates: results of the Turkish HITIT-2 Surveillance Study of 2007. J Chemother 2009; 21:383-389.
  • Azap OK, Arslan H, Serefhanoğlu K et al. Risk factors for ex- tended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 2010; 16:147-151.
  • Livermore DM, Mushtaq S, Nguyen T, Warner M. Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae. Int J Antimicrob Agents 2011; 37:405-409.

In-vitro activity of oxymino-cephalosporins with and without sulbactam against Class A Extended-spectrum β-lactamase producing E.coli

Year 2011, Volume: 1 Issue: 03, 87 - 92, 01.09.2011
https://doi.org/10.5799/ahinjs.02.2011.03.0022

Abstract

References

  • Bush K, Jacoby GA. Updated functional classification of beta- lactamases. Antimicrob Agents Chemother 2010; 54:969- 976.
  • Akinci E, Vahaboglu H. Minor extended-spectrum β-lactamases. Expert Rev Anti Infect Ther 2010; 8:1251-1258.
  • Coque TM, Novais A, Carattoli A et al. Dissemination of clon- ally related Escherichia coli strains expressing extended- spectrum beta-lactamase CTX-M-15. Emerg Infect Dis 2008; 14:195-200.
  • Nicolas-Chanoine M, Blanco J, Leflon-Guibout V et al. Inter- continental emergence of Escherichia coli clone O25:H4- ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 61:273-281.
  • Marchaim D, Gottesman T, Schwartz O et al. National multi- center study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae produc- ing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2010; 54:5099-5104.
  • Tumbarello M, Sanguinetti M, Montuori E et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacte- riaceae: importance of inadequate initial antimicrobial treat- ment. Antimicrob Agents Chemother 2007; 51:1987-1994.
  • Clinical and Laboratory Standards Institute (2010.): Perfor- mance standards for antimicrobial susceptibility testing. Twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI; 2010 CLSI.
  • Clermont O, Dhanji H, Upton M et al. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother 2009; 64:274-277.
  • Vahaboglu H, Budak F, Kasap M et al. High prevalence of OXA-51-type class D beta-lactamases among ceftazidime- resistant clinical isolates of Acinetobacter spp.: co-existence with OXA-58 in multiple centres. J Antimicrob Chemother 2006; 58:537-542.
  • European Committee on Antimicrobial Susceptibility Testing (EUCAST). European Committee on Antimicrobial Suscepti- bility Testing (EUCAST) http://www.eucast.org [accessed 26 May 2010].
  • Akhan S, Coskunkan F, Tansel O, Vahaboglu H. Conjugative resistance to tazobactam plus piperacillin among extended- spectrum beta-lactamase-producing nosocomial Klebsiella pneumoniae. Scand J Infect Dis 2001; 33:512-515.
  • Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hsueh P. Comparison of CLSI 2009, CLSI 2010 and EUCAST ceph- alosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxy- toca from the SMART Global Surveillance Study. Int J Anti- microb Agents 2010; 36:293-294.
  • Foulds G, Stankewich JP, Marshall DC et al. Pharmacokinet- ics of sulbactam in humans. Antimicrob Agents Chemother 1983; 23:692-699.
  • Pfaller MA, Barry AL, Fuchs PC, Gerlach EH, Hardy DJ, McLaughlin JC. Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-nega- tive bacilli to ampicillin and ampicillin/sulbactam. Eur J Clin Microbiol Infect Dis 1993; 12:356-362.
  • Gur D, Hascelik G, Aydin N et al. Antimicrobial resistance in gram-negative hospital isolates: results of the Turkish HITIT-2 Surveillance Study of 2007. J Chemother 2009; 21:383-389.
  • Azap OK, Arslan H, Serefhanoğlu K et al. Risk factors for ex- tended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 2010; 16:147-151.
  • Livermore DM, Mushtaq S, Nguyen T, Warner M. Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae. Int J Antimicrob Agents 2011; 37:405-409.
There are 17 citations in total.

Details

Primary Language English
Journal Section ART
Authors

Fetiye Kolaylı This is me

Cansu Semiz This is me

Haluk Vahaboğlu This is me

Publication Date September 1, 2011
Published in Issue Year 2011 Volume: 1 Issue: 03

Cite

APA Kolaylı, F., Semiz, C., & Vahaboğlu, H. (2011). In-vitro activity of oxymino-cephalosporins with and without sulbactam against Class A Extended-spectrum β-lactamase producing E.coli. Journal of Microbiology and Infectious Diseases, 1(03), 87-92. https://doi.org/10.5799/ahinjs.02.2011.03.0022
AMA Kolaylı F, Semiz C, Vahaboğlu H. In-vitro activity of oxymino-cephalosporins with and without sulbactam against Class A Extended-spectrum β-lactamase producing E.coli. J Microbil Infect Dis. September 2011;1(03):87-92. doi:10.5799/ahinjs.02.2011.03.0022
Chicago Kolaylı, Fetiye, Cansu Semiz, and Haluk Vahaboğlu. “In-Vitro Activity of Oxymino-Cephalosporins With and Without Sulbactam Against Class A Extended-Spectrum β-Lactamase Producing E.Coli”. Journal of Microbiology and Infectious Diseases 1, no. 03 (September 2011): 87-92. https://doi.org/10.5799/ahinjs.02.2011.03.0022.
EndNote Kolaylı F, Semiz C, Vahaboğlu H (September 1, 2011) In-vitro activity of oxymino-cephalosporins with and without sulbactam against Class A Extended-spectrum β-lactamase producing E.coli. Journal of Microbiology and Infectious Diseases 1 03 87–92.
IEEE F. Kolaylı, C. Semiz, and H. Vahaboğlu, “In-vitro activity of oxymino-cephalosporins with and without sulbactam against Class A Extended-spectrum β-lactamase producing E.coli”, J Microbil Infect Dis, vol. 1, no. 03, pp. 87–92, 2011, doi: 10.5799/ahinjs.02.2011.03.0022.
ISNAD Kolaylı, Fetiye et al. “In-Vitro Activity of Oxymino-Cephalosporins With and Without Sulbactam Against Class A Extended-Spectrum β-Lactamase Producing E.Coli”. Journal of Microbiology and Infectious Diseases 1/03 (September 2011), 87-92. https://doi.org/10.5799/ahinjs.02.2011.03.0022.
JAMA Kolaylı F, Semiz C, Vahaboğlu H. In-vitro activity of oxymino-cephalosporins with and without sulbactam against Class A Extended-spectrum β-lactamase producing E.coli. J Microbil Infect Dis. 2011;1:87–92.
MLA Kolaylı, Fetiye et al. “In-Vitro Activity of Oxymino-Cephalosporins With and Without Sulbactam Against Class A Extended-Spectrum β-Lactamase Producing E.Coli”. Journal of Microbiology and Infectious Diseases, vol. 1, no. 03, 2011, pp. 87-92, doi:10.5799/ahinjs.02.2011.03.0022.
Vancouver Kolaylı F, Semiz C, Vahaboğlu H. In-vitro activity of oxymino-cephalosporins with and without sulbactam against Class A Extended-spectrum β-lactamase producing E.coli. J Microbil Infect Dis. 2011;1(03):87-92.